AbbVie (NYSE:ABBV) Stock Price Down 2.8% – Here’s Why

AbbVie Inc. (NYSE:ABBV)’s share price traded down 2.8% on Monday . The stock traded as low as $211.69 and last traded at $212.0390. 8,868,378 shares were traded during trading, an increase of 38% from the average session volume of 6,414,478 shares. The stock had previously closed at $218.04.

Analyst Ratings Changes

A number of brokerages have weighed in on ABBV. Raymond James Financial set a $256.00 price target on shares of AbbVie in a research note on Monday. Erste Group Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating in a research note on Tuesday, October 14th. Guggenheim lifted their price target on shares of AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a research note on Monday, October 20th. JPMorgan Chase & Co. lifted their price target on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday. Finally, Hsbc Global Res lowered shares of AbbVie from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $237.85.

AbbVie Stock Down 2.8%

The company has a market capitalization of $374.58 billion, a price-to-earnings ratio of 100.97, a P/E/G ratio of 1.42 and a beta of 0.51. The stock’s fifty day moving average price is $222.42 and its 200-day moving average price is $201.15. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The business had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The firm’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same period in the previous year, the company earned $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, sell-side analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a $1.73 dividend. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a dividend yield of 3.3%. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio is presently 524.24%.

Insider Buying and Selling at AbbVie

In other AbbVie news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the company’s stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total value of $8,407,055.40. Following the transaction, the executive vice president directly owned 177,292 shares in the company, valued at $35,178,278.64. The trade was a 19.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Nicholas Donoghoe sold 13,295 shares of the company’s stock in a transaction on Tuesday, August 5th. The shares were sold at an average price of $198.51, for a total transaction of $2,639,190.45. Following the completion of the transaction, the executive vice president owned 58,247 shares in the company, valued at approximately $11,562,611.97. This represents a 18.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.25% of the stock is owned by insiders.

Institutional Investors Weigh In On AbbVie

A number of institutional investors have recently modified their holdings of ABBV. Marshall & Sullivan Inc. WA bought a new stake in shares of AbbVie in the second quarter valued at about $25,000. Evolution Wealth Management Inc. bought a new stake in AbbVie during the second quarter worth about $26,000. TD Capital Management LLC lifted its position in AbbVie by 82.9% during the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after purchasing an additional 58 shares during the period. Spurstone Advisory Services LLC bought a new stake in AbbVie during the second quarter worth about $28,000. Finally, Abound Financial LLC bought a new stake in AbbVie during the first quarter worth about $30,000. Institutional investors own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.